Comparison · NCT02979899-39d12435
TRC105 + Votrient vs Votrient: Objective Response Rate of Patients With Unresectable Angiosarcoma
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. TRC105 + Votrient vs Votrient: Objective Response Rate of Patients With Unresectable Angiosarcoma. Trial comparisons, record NCT02979899-39d12435. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02979899-39d12435
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0484 | 0.0166 | 0.133 | wilson | |
| Risk in group 2 | 0.131 | 0.068 | 0.238 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0828 | -0.194 | 0.0227 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.369 | 0.103 | 1.33 | log | |
| Odds ratio, group 1 over group 2 | 0.337 | 0.0849 | 1.34 | log | |
| Number needed to treat, for one fewer participant with the outcome on TRC105 + Votrient than on Votrient | 12.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | TRC105 + Votrient | Weekly TRC105 i.v. in combination with standard dose votrient by mouth, once daily~TRC105: TRC105 antibody~Votrient: pazopanib | 3 | 62 | OG000 |
| Group 2 | Votrient | Standard dose votrient by mouth, once daily~Votrient: pazopanib | 8 | 61 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Objective Response Rate of Patients With Unresectable Angiosarcoma
- Description
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions: Complete Response (CR) is disappearance of all target lesions; Partial Response (PR) is \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Overall response rate is defined as the number of patients with a best response designation of complete response or partial response recorded between the date of randomization and the date of documented progression.
- Time frame
- from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to cut off date of interim analysis (25 months)
- Population
- All patients randomized onto study by cut off date of interim analysis
Source ClinicalTrials.gov
Trial
- Title
- Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma
- NCT number
- NCT02979899
- Phases
- PHASE3
- Conditions
- Advanced Angiosarcoma
- Interventions
- TRC105, Votrient
- Lead sponsor
- Tracon Pharmaceuticals Inc.
- Results first posted
- 2020-05-12
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02979899?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02979899-39d12435